<DOC>
	<DOCNO>NCT00467194</DOCNO>
	<brief_summary>RATIONALE : Sirolimus may stop growth tumor cell block enzymes need cell growth . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab sirolimus may also stop growth liver cancer block blood flow tumor . Giving sirolimus together bevacizumab may kill tumor cell . PURPOSE : This phase I trial study side effect best dose sirolimus give together bevacizumab treat patient liver cancer remove surgery .</brief_summary>
	<brief_title>Sirolimus Bevacizumab Treating Patients With Liver Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose sirolimus use combination bevacizumab patient unresectable hepatocellular carcinoma . - Determine toxicity profile regimen patient . Secondary - Determine clinical activity regimen patient . - Determine pharmacokinetics sirolimus patient . - Determine biologically active dose range sirolimus patient . - Correlate phosphorylated p70S6K activity clinical response patient treat regimen . - Correlate PTEN , 4EBP-1 , phosphorylated p70S6K , CD31 , vascular endothelial growth factor expression clinical response patient treat regimen . - Correlate degree angiogenesis ( measure DCE-CT scan ) drug level clinical response . OUTLINE : This dose-escalation study sirolimus . Patients receive bevacizumab IV 30-90 minute every 2 week oral sirolimus daily . Treatment continue 6 month absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos sirolimus maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Six additional patient receive treatment MTD . Blood sample collect healthy participant measure p70S6 kinase activity . Patients undergo blood sample collection baseline periodically study pharmacokinetic p70S6K activity assessment . Samples also analyze high-performance liquid chromatography tandem mass spectrophotometry determine peak drug concentration . Patients without archived tumor sample undergo tumor tissue biopsy baseline . Samples analyze PTEN , 4E-BP1 , vascular endothelial growth factor , epidermal growth factor , p70S6K , CD31 immunohistochemistry . Patients also undergo DCE-CT scan baseline day 29 ass angiogenesis . After completion study treatment , patient follow 52 week . PROJECTED ACCRUAL : A total 36 patient 5 healthy participant accrue study .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meets 1 follow criterion : Histologically confirm unresectable hepatocellular carcinoma , meet follow criterion : Failed 02 line chemotherapy ChildPugh class A B liver cirrhosis Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan No known brain metastases Bone metastasis allow provide measurable disease present Healthy participant PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 Karnofsky PS 70100 % Life expectancy &gt; 3 month WBC ≥ 3,000/mm³ Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 3 time upper limit normal ( ULN ) AST ALT ≤ 5 time ULN Creatinine normal PTT &lt; 1.5 time ULN Fasting serum cholesterol ≤ 350 mg/dL Triglycerides ≤ 300 mg/dL Proteinuria &lt; 2+ urine dipstick OR urine protein ≤ 1 g 24hour urine collection No history allergic reaction compound similar chemical biologic composition sirolimus bevacizumab No prior thromboembolic disease may result bleed clot problem relate use bevacizumab include , limited , follow : Esophageal varix Bleeding disorder Deep vein thrombose No history hematemesis hemoptysis No uncontrolled illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would preclude study participation No HIV positivity Able take oral medication Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception prior course study treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics More 28 day since prior surgery recover No concurrent investigational agent No concurrent anticancer therapy No concurrent traditional Chinese medicine ( ) No concurrent long term anticoagulation heparin warfarin Concurrent prophylactic lowdose acetylsalicylic acid patient risk arterial thromboembolic event allow Hepatitis B carrier must lamivudine 6 month completion study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
</DOC>